Shows
Hematologic Oncology UpdateNon-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual MeetingDr Jeremy Abramson from Massachusetts General Hospital in Boston, Dr Joshua Brody from the Tisch Cancer Institute in New York, New York, Dr Christopher Flowers from The University of Texas MD Anderson Cancer Center in Houston, Dr Ann LaCasce from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Tycel Phillips from City of Hope Comprehensive Cancer Center in Duarte, California, discuss patient cases and provide their perspectives on clinical datasets informing the care of patients with non-Hodgkin lymphoma. CME information and select publications here. 2025-07-101h 59
Research To Practice | Oncology VideosNon-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual MeetingFeaturing perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Christopher Flowers, Dr Ann LaCasce and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics: Introduction (0:00) Selection and Sequencing of Available Therapies for Diffuse Large B-Cell Lymphoma — Dr Flowers (2:24) Evolving Management Paradigm for Mantle Cell Lymphoma — Dr Phillips (31:53) Integration of Novel Therapies into the Management of Follicular Lymphoma — Dr LaCasce (54:51) Integrating Bispecific Antibodies into the Management of Non-Hodgkin Lymphoma (NHL) — Dr Brody (1:11:22) Current Role of CAR T-Cell Therapy in Various NHL Subtypes — Dr Abramson (1:37:55) CME information and select publications2025-07-091h 59
Oncology Today with Dr Neil LoveNon-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual MeetingDr Jeremy Abramson from Massachusetts General Hospital in Boston, Dr Joshua Brody from the Tisch Cancer Institute in New York, New York, Dr Christopher Flowers from The University of Texas MD Anderson Cancer Center in Houston, Dr Ann LaCasce from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Tycel Phillips from City of Hope Comprehensive Cancer Center in Duarte, California, discuss patient cases and provide their perspectives on clinical datasets informing the care of patients with non-Hodgkin lymphoma. CME information and select publications here. 2025-07-091h 59
OncLive® On AirStrong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMScIn this week's episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, spoke with Ann S. LaCasce, MD, MMSc, an associate professor of medicine and a lymphoma specialist at Dana-Farber Cancer Institute in Boston, Massachusetts and Director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology. LaCasce shares her journey into hematologic oncology, shaped by early mentors—including her father—and how a passion for art history sparked her interest in pattern recognition and morphology, which are skills central to lymphoma diagnosis.
Their discussion explores key adva...2025-03-2620 min
Cancer QuestionsI Found a Lump on My Body. Now What?Ann LaCasce, MD, oncologist at Dana-Farber Cancer Institute, explains what to do if you discover a lump or enlarged lymph node on your body. Learn why consulting a medical professional is crucial for identifying potential causes, such as infections or other conditions, and determining whether further steps like imaging or a biopsy are needed.Want to learn more about early detection and cancer care? Visit: https://www.dana-farber.org/2025-03-1001 min
Research To Practice | Oncology VideosHodgkin and Non-Hodgkin Lymphoma | Third Annual National General Medical Oncology SummitFeaturing perspectives from Dr Ann S LaCasce, Dr Matthew Lunning, Dr Kami Maddocks and Dr Andrew D Zelenetz, including the following topics. Introduction (0:00) Follicular Lymphoma (FL) — Dr Zelenetz (2:29) Mantle Cell Lymphoma (MCL) — Dr Lunning (32:04) Hodgkin Lymphoma (HL) — Dr LaCasce (1:00:36) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Maddocks (1:18:53) CME information and select publications2024-04-191h 39
Research To Practice | Oncology VideosHER2-Positive and Triple-Negative Breast Cancer | Oncology in the Real World: A Daylong Multitumor Educational Symposium in Partnership with the American Oncology NetworkFeaturing perspectives from Prof Mitesh J Borad, Dr Anthony El-Khoueiry, Dr Christopher R Flowers, Dr Sara A Hurvitz, Dr Thomas E Hutson, Dr Amrita Krishnan, Dr Ann S LaCasce, Dr Heather McArthur, Dr Bradley J Monk, Dr Kathleen N Moore, Dr Robert Z Orlowski and Dr Guru P Sonpavde, moderated by Dr Neil Love, co-moderated by Dr Stephen “Fred” Divers, including the following topics: Introduction (0:00) Triple-Negative Breast Cancer — Heather McArthur, MD, MPH (6:59) HER2-Positive Breast Cancer — Sara A Hurvitz, MD, FACP (44:04) CME information and select publications2023-11-031h 01
Research To Practice | Oncology VideosMultiple Myeloma | Oncology in the Real World: A Daylong Multitumor Educational Symposium in Partnership with the American Oncology NetworkFeaturing perspectives from Prof Mitesh J Borad, Dr Anthony El-Khoueiry, Dr Christopher R Flowers, Dr Sara A Hurvitz, Dr Thomas E Hutson, Dr Amrita Krishnan, Dr Ann S LaCasce, Dr Heather McArthur, Dr Bradley J Monk, Dr Kathleen N Moore, Dr Robert Z Orlowski and Dr Guru P Sonpavde, moderated by Dr Neil Love, co-moderated by Dr Stephen “Fred” Divers, including the following topics: Introduction (0:00) Optimizing the Current Management of Multiple Myeloma — Robert Z Orlowski, MD, PhD (3:44) CAR (Chimeric Antigen Receptor) T-Cell Therapy, Bispecific Antibodies and Other Novel Approaches — Amrita Krishnan, MD (32:37) CME information and select publications2023-11-031h 05
Research To Practice | Oncology VideosGynecologic Cancers | Oncology in the Real World: A Daylong Multitumor Educational Symposium in Partnership with the American Oncology NetworkFeaturing perspectives from Prof Mitesh J Borad, Dr Anthony El-Khoueiry, Dr Christopher R Flowers, Dr Sara A Hurvitz, Dr Thomas E Hutson, Dr Amrita Krishnan, Dr Ann S LaCasce, Dr Heather McArthur, Dr Bradley J Monk, Dr Kathleen N Moore, Dr Robert Z Orlowski and Dr Guru P Sonpavde, moderated by Dr Neil Love, co-moderated by Dr Stephen “Fred” Divers, including the following topics: Introduction (0:00) Ovarian Cancer — Kathleen N Moore, MD, MS (4:14) Endometrial and Cervical Cancers — Bradley J Monk, MD (41:09) CME information and select publications2023-11-0359 min
Research To Practice | Oncology VideosHepatobiliary and Pancreatic Cancers | Oncology in the Real World: A Daylong Multitumor Educational Symposium in Partnership with the American Oncology NetworkFeaturing perspectives from Prof Mitesh J Borad, Dr Anthony El-Khoueiry, Dr Christopher R Flowers, Dr Sara A Hurvitz, Dr Thomas E Hutson, Dr Amrita Krishnan, Dr Ann S LaCasce, Dr Heather McArthur, Dr Bradley J Monk, Dr Kathleen N Moore, Dr Robert Z Orlowski and Dr Guru P Sonpavde, moderated by Dr Neil Love, co-moderated by Dr Stephen “Fred” Divers, including the following topics: Introduction (0:00) Biliary Tract and Pancreatic Cancer — Mitesh J Borad, MD (3:42) Hepatocellular Carcinoma — Anthony El-Khoueiry, MD (33:25) CME information and select publications2023-11-0358 min
Research To Practice | Oncology VideosUrothelial Bladder Cancer and Renal Cell Carcinoma | Oncology in the Real World: A Daylong Multitumor Educational Symposium in Partnership with the American Oncology NetworkFeaturing perspectives from Prof Mitesh J Borad, Dr Anthony El-Khoueiry, Dr Christopher R Flowers, Dr Sara A Hurvitz, Dr Thomas E Hutson, Dr Amrita Krishnan, Dr Ann S LaCasce, Dr Heather McArthur, Dr Bradley J Monk, Dr Kathleen N Moore, Dr Robert Z Orlowski and Dr Guru P Sonpavde, moderated by Dr Neil Love, co-moderated by Dr Stephen “Fred” Divers, including the following topics: Introduction (0:00) Renal Cell Carcinoma — Thomas E Hutson, DO, PharmD (6:19) Urothelial Bladder Cancer — Guru P Sonpavde, MD (34:59) CME information and select publications 2023-11-0356 min
Research To Practice | Oncology VideosLymphoma | Oncology in the Real World: A Daylong Multitumor Educational Symposium in Partnership with the American Oncology NetworkFeaturing perspectives from Prof Mitesh J Borad, Dr Anthony El-Khoueiry, Dr Christopher R Flowers, Dr Sara A Hurvitz, Dr Thomas E Hutson, Dr Amrita Krishnan, Dr Ann S LaCasce, Dr Heather McArthur, Dr Bradley J Monk, Dr Kathleen N Moore, Dr Robert Z Orlowski and Dr Guru P Sonpavde, moderated by Dr Neil Love, co-moderated by Dr Stephen “Fred” Divers, including the following topics: Introduction (0:00) Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma — Ann S LaCasce, MD, MMSc (8:26) Follicular Lymphoma and Mantle Cell Lymphoma — Christopher R Flowers, MD, MS (42:55) CME information and select publications2023-11-031h 05
WEEI/NESN Jimmy Fund Radio-TelethonMary Worthington Kachadurian, 65, follicular lymphoma, Boston, with Ann S. LaCasce, MD, MMSc, Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/OncologyBlood in her urine lead Mary to get a kidney stone scan, but incidentally revealed that she had lymphoma. She immediately called Dana-Farber and was connected with the Cancer Diagnostic Service at Dana-Farber Brigham Cancer Center, which was new at the time of her lymphoma finding in 2018. The staff there cared for and led her through an expedited process to an official diagnosis of follicular lymphoma. At the same time, Mary had been training for the 2018 Pan Mass Challenge. She started chemotherapy in the in the fall of 2018, every 3 weeks for 6 cycles, because the cancer had become...2023-08-2908 min
Research To Practice | Oncology VideosLymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma | Meet The Professors Live: Clinical Investigators Provide Perspectives on Actual Cases of Patients with Lymphoma, Chronic Lymphocytic Leukemia and Multiple MyelomaFeaturing perspectives from Dr John N Allan, Dr Shaji K Kumar, Dr Ann S LaCasce, Dr Sagar Lonial, Dr Loretta J Nastoupil and Dr Susan O’Brien, including the following topics: Multiple Myeloma Introduction (0:00) Initial treatment of newly diagnosed multiple myeloma (MM) (1:51) Sequencing of therapies for relapsed/refractory MM (21:34) Lymphoma Hodgkin lymphoma (52:12) Diffuse large B-cell lymphoma and follicular lymphoma (1:05:30) Mantle cell lymphoma (1:31:17) Chronic Lymphocytic Leukemia First-line treatment of chronic lymphocytic leukemia (1:41:23) Relapsed/refractory disease (2:14:23) Richter’s transformation (2:22:50) CME information and select publications2023-07-052h 30
The Medicine Mentors PodcastBuilding a Mentorship Mosaic with Dr. Ann LaCasceAnn LaCasce, MD, is the Director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and an Associate Professor of Medicine at Harvard Medical School. Dr. LaCasce completed her medical school from Tufts University and residency in Internal Medicine at Brigham and Women’s Hospital where she later served as Chief Medical Resident, followed by a fellowship in Hematology/Oncology at the Dana-Farber Cancer Institute. She is a nationally renowned lymphoma specialist, chairs the steering committee for Women in Lymphoma and is currently serving as Chair-elect of the Lymphoma Research Foundation. “You’re never going to find one person who can...2023-03-0820 min
Research To Practice | Oncology VideosChronic Lymphocytic Leukemia and Lymphomas | Proceedings from a Daylong Multitumor Educational Symposium in Partnership with Florida Cancer SpecialistsProceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas. Featuring perspectives from Drs Ann LaCasce and Mitchell Smith, including the following topics: Hodgkin Lymphoma and CLL (0:00) Bispecific Antibodies, CAR T-Cell Therapy; Diffuse Large B-Cell Lymphoma (32:31) Treatment for Mantle Cell Lymphoma (53:23) CME information and select publications2022-11-161h 01
VJHemOnc PodcastEHA & ICML 2021: updates in Hodgkin lymphomaAlthough classical Hodgkin lymphoma has a high cure and overall survival rate, the treatment of relapsed/refractory disease, treatment-related adverse events, impacts on quality of life and poor outcomes in older patients present ongoing unmet needs. Much research is currently focused on risk stratification, such as with positive emission tomography (PET) scans, to identify patients who are at low- or high-risk of recurrence and enable the use of risk-adapted approaches. Furthermore, longer-term follow-up data from trials of novel immunotherapy combinations in the frontline setting have recently been presented which demonstrate durable remissions and may reduce the risk of relapse...2021-08-0612 min
Essential WisdomAnn LaCasce, MD, MMSc - Hematology and OncologyHelp me welcome Dr. Ann LaCasce! Dr. LaCasce practices medical oncology at Dana Farber Cancer Institute in Boston, MA. She is the Director of Dana-Farber/Partners CancerCare Hematology-Medical Oncology Fellowship, an Associate Professor of Medicine at Harvard Medical School, and an Instructor of Medical Oncology at Dana-Farber Cancer Institute. Dr. LaCasce received her MD from Tufts University and went on to complete residency in Internal Medicine at Brigham and Women’s Hospital. She earned her fellowship in Hematology & Oncology Dana-Farber/Partners CancerCare. Her academic interests include Hodgkin/Non-Hodgkin lymphoma and the study of novel treatment agents. She is also ac...2020-01-3024 min
WEEI/NESN Jimmy Fund Radio-TelethonJimmy Fund social media coordinator and Dana-Farber Hodgkin lymphoma patient Chloe Svolos with Dr. Ann LaCasce on tailoring treatment to patient and the importance of a support systemChloe Svolos was diagnosed with Hodgkin lymphoma after her doctor thought a lump in her throat was probably not cancer, but wanted her to get it scanned anyway. Chloe received the diagnosis the same she and her boyfriend moved in together. Along with Chloe is Dr. Ann LaCasce, medical oncologist in the adult lymphoma program at Dana-Farber.2019-08-2105 min
Journal of Clinical Oncology (JCO) PodcastThe Need for Continued Vigilance in Patients with Diffuse Large B-Cell LymphomaThis JCO Podcast provides observations and commentary on the JCO article 'Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy' by Yang et My name is Ann LaCasce, and I am an Associate Professor of Medicine at the Dana-Farber Cancer Institute in Boston, USA. My oncologic specialty is lymphoma. This podcast discusses the recent paper evaluating the risk of late relapse in patients with diffuse large B-cell lymphoma who are event free 24 months after diagnosis. The goal of upfront chemoimmunotherapy in patients with diffuse large B-cell lymphoma (DLBCL) is the p...2019-06-0606 min
Journal of Clinical Oncology (JCO) PodcastThe Need for Continued Vigilance in Patients with Diffuse Large B-Cell LymphomaThis JCO Podcast provides observations and commentary on the JCO article 'Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy' by Yang et My name is Ann LaCasce, and I am an Associate Professor of Medicine at the Dana-Farber Cancer Institute in Boston, USA. My oncologic specialty is lymphoma. This podcast discusses the recent paper evaluating the risk of late relapse in patients with diffuse large B-cell lymphoma who are event free 24 months after diagnosis. The goal of upfront chemoimmunotherapy in patients with diffuse large B-cell lymphoma (DLBCL) is the p...2019-06-0606 min
Chronic lymphoblastic leukemia - The Bloodline with LLSCLL: Risk Factors, Resources and Research
Ann LaCasce, MD
Join Alicia and Lizette from The Leukemia and Lymphoma Society as they speak with Dr. Ann LaCasce, Program Director of the Dana-Farber/ Partners CancerCare Fellowship, the largest hematology/oncology training program in the country. On this episode, Dr. LaCasce explains the difference between chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), CLL and its connection with Agent Orange exposure, resources available for Veterans, current and emerging therapies, clinical trials and the importance of medication adherence. Dr. LaCasce shares her excitement for what is to come for CLL treatment and her appreciation for fellow providers around the world, who...2019-01-2226 min
The Bloodline with LLSCLL: Risk Factors, Resources and ResearchJoin Alicia and Lizette from The Leukemia and Lymphoma Society as they speak with Dr. Ann LaCasce, Program Director of the Dana-Farber/ Partners CancerCare Fellowship, the largest hematology/oncology training program in the country. On this episode, Dr. LaCasce explains the difference between chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), CLL and its connection with Agent Orange exposure, resources available for Veterans, … CLL: Risk Factors, Resources and Research Read More »2019-01-2226 min
Chronic lymphoblastic leukemia - The Bloodline with LLSCLL: Risk Factors, Resources and Research
Ann LaCasce, MD
Join Alicia and Lizette from The Leukemia and Lymphoma Society as they speak with Dr. Ann LaCasce, Program Director of the Dana-Farber/ Partners CancerCare Fellowship, the largest hematology/oncology training program in the country. On this episode, Dr. LaCasce explains the difference between chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), CLL and its connection with Agent Orange exposure, resources available for Veterans, current and emerging therapies, clinical trials and the importance of medication adherence. Dr. LaCasce shares her excitement for what is to come for CLL treatment and her appreciation for fellow providers around the world, who...2019-01-2226 minEpisodes - The Bloodline with LLSCLL: Risk Factors, Resources and Research
Ann LaCasce, MD
Join Alicia and Lizette from The Leukemia and Lymphoma Society as they speak with Dr. Ann LaCasce, Program Director of the Dana-Farber/ Partners CancerCare Fellowship, the largest hematology/oncology training program in the country. On this episode, Dr. LaCasce explains the difference between chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), CLL and its connection with Agent Orange exposure, resources available for Veterans, current and emerging therapies, clinical trials and the importance of medication adherence. Dr. LaCasce shares her excitement for what is to come for CLL treatment and her appreciation for fellow providers around the world, who...2019-01-2226 minLeukemia - The Bloodline with LLSCLL: Risk Factors, Resources and Research
Ann LaCasce, MD
Join Alicia and Lizette from The Leukemia and Lymphoma Society as they speak with Dr. Ann LaCasce, Program Director of the Dana-Farber/ Partners CancerCare Fellowship, the largest hematology/oncology training program in the country. On this episode, Dr. LaCasce explains the difference between chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), CLL and its connection with Agent Orange exposure, resources available for Veterans, current and emerging therapies, clinical trials and the importance of medication adherence. Dr. LaCasce shares her excitement for what is to come for CLL treatment and her appreciation for fellow providers around the world, who...2019-01-2226 minEnglish – The Bloodline with LLSCLL: Risk Factors, Resources and ResearchAnn LaCasce, MD
Join Alicia and Lizette from The Leukemia and Lymphoma Society as they speak with Dr. Ann LaCasce, Program Director of the Dana-Farber/ Partners CancerCare Fellowship, the largest hematology/oncology training program in the country. On this episode, Dr. LaCasce explains the difference between chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), CLL and its connection with Agent Orange exposure, resources available for Veterans, current and emerging therapies, clinical trials and the importance of medication adherence. Dr. LaCasce shares her excitement for what is to come for CLL treatment and her appreciation for fellow providers arou...2019-01-2226 minThe Bloodline with LLSCLL: Risk Factors, Resources and ResearchJoin Alicia and Lizette from The Leukemia and Lymphoma Society as they speak with Dr. Ann LaCasce, Program Director of the Dana-Farber/…
The post CLL: Risk Factors, Resources and Research first appeared on The Bloodline with LLS.2019-01-2226 minEnglish - The Bloodline with LLSCLL: Risk Factors, Resources and Research
Ann LaCasce, MD
Join Alicia and Lizette from The Leukemia and Lymphoma Society as they speak with Dr. Ann LaCasce, Program Director of the Dana-Farber/ Partners CancerCare Fellowship, the largest hematology/oncology training program in the country. On this episode, Dr. LaCasce explains the difference between chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), CLL and its connection with Agent Orange exposure, resources available for Veterans, current and emerging therapies, clinical trials and the importance of medication adherence. Dr. LaCasce shares her excitement for what is to come for CLL treatment and her appreciation for fellow providers around the world, who...2019-01-2226 minThe Bloodline with LLSUnderstanding a CLL DiagnosisListen in as Alicia and Lizette chat with Dr. Ann LaCasce, a Program Director of the Dana-Farber/ Partners CancerCare Fellowship, the largest hematology/oncology training program in the country. While studying pre-med, Dr. LaCasce took additional classes that piqued her interest in art history. After managing an art gallery in New York for five years and returning to medical … Understanding a CLL Diagnosis Read More »2018-12-1733 minLeukemia - The Bloodline with LLSUnderstanding a CLL Diagnosis
Ann LaCasce, MD
Listen in as Alicia and Lizette chat with Dr. Ann LaCasce, a Program Director of the Dana-Farber/ Partners CancerCare Fellowship, the largest hematology/oncology training program in the country. While studying pre-med, Dr. LaCasce took additional classes that piqued her interest in art history. After managing an art gallery in New York for five years and returning to medical school, she found that being visually oriented allowed her to approach hematology with creativity while caring for her patients. Join in as Dr. LaCasce discusses diagnosis and treatment of chronic lymphocytic leukemia (CLL), small cell lymphocytic lymphoma (SLL...2018-12-1733 minEnglish - The Bloodline with LLSUnderstanding a CLL Diagnosis
Ann LaCasce, MD
Listen in as Alicia and Lizette chat with Dr. Ann LaCasce, a Program Director of the Dana-Farber/ Partners CancerCare Fellowship, the largest hematology/oncology training program in the country. While studying pre-med, Dr. LaCasce took additional classes that piqued her interest in art history. After managing an art gallery in New York for five years and returning to medical school, she found that being visually oriented allowed her to approach hematology with creativity while caring for her patients. Join in as Dr. LaCasce discusses diagnosis and treatment of chronic lymphocytic leukemia (CLL), small cell lymphocytic lymphoma (SLL...2018-12-1733 minThe Bloodline with LLSUnderstanding a CLL DiagnosisListen in as Alicia and Lizette chat with Dr. Ann LaCasce, a Program Director of the Dana-Farber/ Partners CancerCare Fellowship, the…
The post Understanding a CLL Diagnosis first appeared on The Bloodline with LLS.2018-12-1733 minEnglish – The Bloodline with LLSUnderstanding a CLL DiagnosisAnn LaCasce, MD
Listen in as Alicia and Lizette chat with Dr. Ann LaCasce, a Program Director of the Dana-Farber/ Partners CancerCare Fellowship, the largest hematology/oncology training program in the country. While studying pre-med, Dr. LaCasce took additional classes that piqued her interest in art history. After managing an art gallery in New York for five years and returning to medical school, she found that being visually oriented allowed her to approach hematology with creativity while caring for her patients. Join in as Dr. LaCasce discusses diagnosis and treatment of chronic lymphocytic leukemia (CLL), small cell lymph...2018-12-1733 minEpisodes - The Bloodline with LLSUnderstanding a CLL Diagnosis
Ann LaCasce, MD
Listen in as Alicia and Lizette chat with Dr. Ann LaCasce, a Program Director of the Dana-Farber/ Partners CancerCare Fellowship, the largest hematology/oncology training program in the country. While studying pre-med, Dr. LaCasce took additional classes that piqued her interest in art history. After managing an art gallery in New York for five years and returning to medical school, she found that being visually oriented allowed her to approach hematology with creativity while caring for her patients. Join in as Dr. LaCasce discusses diagnosis and treatment of chronic lymphocytic leukemia (CLL), small cell lymphocytic lymphoma (SLL...2018-12-1733 minChronic lymphoblastic leukemia - The Bloodline with LLSUnderstanding a CLL Diagnosis
Ann LaCasce, MD
Listen in as Alicia and Lizette chat with Dr. Ann LaCasce, a Program Director of the Dana-Farber/ Partners CancerCare Fellowship, the largest hematology/oncology training program in the country. While studying pre-med, Dr. LaCasce took additional classes that piqued her interest in art history. After managing an art gallery in New York for five years and returning to medical school, she found that being visually oriented allowed her to approach hematology with creativity while caring for her patients. Join in as Dr. LaCasce discusses diagnosis and treatment of chronic lymphocytic leukemia (CLL), small cell lymphocytic lymphoma (SLL...2018-12-1733 minChronic lymphoblastic leukemia - The Bloodline with LLSUnderstanding a CLL DiagnosisAnn LaCasce, MD
Listen in as Alicia and Lizette chat with Dr. Ann LaCasce, a Program Director of the Dana-Farber/ Partners CancerCare Fellowship, the largest hematology/oncology training program in the country. While studying pre-med, Dr. LaCasce took additional classes that piqued her interest in art history. After managing an art gallery in New York for five years and returning to medical school, she found that being visually oriented allowed her to approach hematology with creativity while caring for her patients. Join in as Dr. LaCasce discusses diagnosis and treatment of chronic lymphocytic leukemia (CLL), small cell lymph...2018-12-1733 min
Understanding Cancer | Dana-Farber Cancer InstituteCancer Mythbusters Episode #4: Is Cancer Contagious?A cancer diagnosis can inspire many questions, one of the most common being, “How did I get this disease?” There are a host of different causes, and in many cases, researchers do not have a definitive answer.
But is it possible for cancer to spread from person to person? In this episode of Cancer Mythbusters, we’ll tackle this question with the help of Dana-Farber's Ann S. LaCasce, MD, MMSc — and explore how to reduce the negative stigma that some cancer patients face as a result of their diagnoses.2017-12-1107 min
The HematologistBCL-2 Is an Effective Target in Chronic Lymphocytic LeukemiaIn her Diffusion article from the May/June issue of The Hematologist, Dr. Ann LaCasce (Dana-Farber Cancer Institute) discusses the use of the recently FDA-approved drug venetoclax for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Dr. Andrew Roberts (Walter + Eliza Hall Institute of Medical Research) shares his thoughts about the drug and his experience with the first phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL/SLL in this thought-provoking conversation. You can find Dr. LaCasce’s Diffusion article online at www.hematology.org/Thehematologist/Diffusion/5479.aspx.
Music: “Jell...2016-05-0327 min
The HematologistNavigating Future Challenges in LymphomaThe strategic roadmap developed at the original ASH Meeting on Lymphoma Biology held in August 2014 was recently published in Blood. To continue this important conversation, Dr. Ann LaCasce (Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA) and Dr. David Weinstock (Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA) have contributed a companion article, just published in the May/June issue of The Hematologist. This podcast features additional insight from the authors, with The Hematologist Editor-in-Chief Dr. Jason Gotlib (Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA) moderating the discussion. Read the article here: http://www.hematology.org/Thehematologist...2015-05-0616 min